Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07082257 · ClinicalTrials.gov registry record

Precision Performance Status Compared With ECOG Performance Status

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by University of Southern California.

Active
Registry status
41
Enrollment target
2
Study locations

NCT07082257 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 41 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07082257, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is active but no longer recruiting, sponsored by University of Southern California.

ACTIVE NOT RECRUITING
Registry status
41 participants
Enrollment target
2
Study locations

Study Summary

This study compares consumer movement trackers to the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) in monitoring cancer patient movement. The ECOG PS emphasizes a patient's ambulatory status (ability to walk around), and scores patients on a scale of 0-5: 0 (no restrictions), 1 (ambulatory), 2 (\< 50% of hours spent in bed, unable to carry out work activities), 3 (\> 50% of hours spent in bed, limited in self care), 4 (bedbound and gravely disabled) and 5 (deceased). Accurate assessment of a patient's PS is paramount in informing therapeutic decision-making, whether it be to predict response and tolerability to treatment or determine eligibility for clinical trials. However, the ECOG PS scale is observational, and therefore limited in its precision. Information gained in this study may help researchers learn if there is a better way to assess patient movement with computerized analysis tools using movement trackers.

Conditions Studied

Malignant Solid Neoplasm Hematopoietic and Lymphatic System Neoplasm

Interventions

  • OTHER Functional Assessment
  • BEHAVIORAL Timed Get Up and Go Test

Study Locations (2)

California

  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2022-11-22
Est. Completion 2026-05-28

Sponsor

University of Southern California

617 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07082257

The ClinicalTrials.gov registry entry for NCT07082257 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Functional Assessment is the first listed.

NCT07082257 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07082257 about?

NCT07082257 is a clinical study titled "Precision Performance Status Compared With ECOG Performance Status". This study compares consumer movement trackers to the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) in monitoring cancer patient movement. The ECOG PS emphasizes a patient's ambulatory status (ability to walk around), and scores patients on a scale of 0-5: 0 (no restrictions), 1 ...

What is the current status of trial NCT07082257?

This trial is currently active not recruiting. The enrollment target is 41 participants. The study started on 2022-11-22. Estimated completion is 2026-05-28.

What conditions does trial NCT07082257 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.

What interventions are being tested in trial NCT07082257?

The interventions under investigation include: Functional Assessment (OTHER), Timed Get Up and Go Test (BEHAVIORAL).

Who is sponsoring clinical trial NCT07082257?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07082257 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Solid Neoplasm

All registered trials for this condition

Hematopoietic and Lymphatic System Neoplasm

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.